Sugi Predict

Sugi Predict / Compounds / SCHEMBL2109002

SCHEMBL2109002

SCHEMBL2109002

CC(=O)NC[C@H]1CN(c2ccc(OCC3(OP(=O)(O)O)CCN(c4cc5c(cc4F)c(=O)c(C(=O)O)cn5C4CC4)CC3)c(F)c2)C(=O)O1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TOP2B Q02880 2/20 0.49
▸ LMNA P02545 4/20 0.46
▸ MAOA P21397 3/20 0.46
▸ MAOB P27338 3/20 0.46
▸ PTGS1 P23219 2/20 0.46
▸ SDHA P31040 2/20 0.46
▸ CALML3 P27482 1/20 0.46
▸ KDM4E B2RXH2 4/20 0.46
▸ ALDH1A1 P00352 4/20 0.46
▸ HPGD P15428 2/20 0.45
▸ HSD17B10 Q99714 2/20 0.45
▸ MAPT P10636 1/20 0.45
▸ CYP1A2 P05177 1/20 0.43
▸ TOP2A P11388 1/20 0.43
▸ CYP2C9 P11712 1/20 0.43
▸ PIK3CG P48736 2/20 0.42
▸ HTT P42858 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ PIK3CD O00329 1/20 0.41
▸ PIK3R1 P27986 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29395141 1.00 TOP2B (0.49) TOP2BLMNAMAOAMAOBPTGS1
SCHEMBL9890815 1.00 TOP2B (0.49) TOP2BLMNAMAOAMAOBPTGS1
SCHEMBL12342304 0.96 TOP2B (0.51) TOP2BLMNAMAOAMAOBPTGS1
SCHEMBL16274030 0.96 TOP2B (0.51) TOP2BLMNAMAOAMAOBPTGS1
SCHEMBL21203139 0.94 TOP2B (0.48) TOP2BLMNAMAOAMAOBPTGS1
SCHEMBL22795065 0.94 KDM4E (0.46) TOP2BLMNAMAOBKDM4EALDH1A1
SCHEMBL22794181 0.93 KDM4E (0.45) TOP2BLMNAKDM4EALDH1A1HPGD
SCHEMBL28488322 0.92 TOP2B (0.51) TOP2BLMNAMAOAMAOBPTGS1
SCHEMBL22642711 0.92 TOP2B (0.51) TOP2BLMNAMAOAMAOBPTGS1
SCHEMBL2108803 0.92 TOP2B (0.47) TOP2BLMNAMAOAMAOBPTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11261205-B2 Oxazolidinone-quinolone hybrid antibacterial for the parenteral treatment of prophylaxis of bacterial diseases MORPHOCHEM GMBH (DE) 2022-03-01 — — US claimed
CN-112089714-A Oxazolidinone-quinolone hybrid antibacterial agents for the parenteral treatment or prophylaxis of bacterial diseases 莫弗凯姆有限公司 2020-12-18 — — CN claimed
US-20200392168-A1 OXAZOLIDINONE-QUINOLONE HYBRID ANTIBACTERIAL FOR THE PARENTERAL TREATMENT OF PROPHYLAXIS OF BACTERIAL DISEASES Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) 2020-12-17 — — US claimed
EP-3003307-B1 COMBINATION THERAPY COMPRISING OXAZOLIDINONE-QUINOLONES FOR USE IN TREATING BACTERIAL INFECTIONS MORPHOCHEM GMBH (DE) 2020-11-11 — — EP claimed
US-10723746-B2 Oxazolidinone-quinolone hybrid antibacterials for the parenteral treatment or prophylaxis of bacterial diseases Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) 2020-07-28 — — US claimed
EP-3517106-A1 OXAZOLIDINONE-QUINOLONE HYBRID ANTIBACTERIALS FOR THE PARENTERAL TREATMENT OR PROPHYLAXIS OF BACTERIAL DISEASES Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) 2019-07-31 — — EP claimed
EP-3003289-B1 ADMINISTRATION OF OXAZOLIDINONE-QUINOLONE HYBRID ANTIBACTERIALS MORPHOCHEM AKTIENGESELLSCHAFT FUER KOMB CHEMIE (DE) 2019-02-20 — — EP claimed
US-9993469-B2 Combination therapy comprising oxazolidinone-quinolones for use in treating bacterial infections Morphochem Aktiengesellschaft Für Kombinatorishe Chemie (DE) 2018-06-12 — — US claimed
US-20160130288-A1 OXAZOLIDINONE-QUINOLONE HYBRID ANTIBACTERIALS FOR THE PARENTERAL TREATMENT OR PROPHYLAXIS OF BACTERIAL DISEASES Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) 2016-05-12 — — US claimed
US-20160113921-A1 COMBINATION THERAPY COMPRISING OXAZOLIDINONE-QUINOLONES FOR USE IN TREATING BACTERIAL INFECTIONS Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) 2016-04-28 — — US claimed
EP-3003289-A1 OXAZOLIDINONE-QUINOLONE HYBRID ANTIBACTERIALS FOR THE PARENTERAL TREATMENT OR PROPHYLAXIS OF BACTERIAL DISEASES Morphochem Aktiengesellschaft Für Kombinatorische Chemie (DE) 2016-04-13 — — EP claimed
WO-2014191075-A1 OXAZOLIDINONE-QUINOLONE HYBRID ANTIBACTERIALS FOR THE PARENTERAL TREATMENT OR PROPHYLAXIS OF BACTERIAL DISEASES Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) 2014-12-04 — — WO claimed
US-11261205-B2 Oxazolidinone-quinolone hybrid antibacterial for the parenteral treatment of prophylaxis of bacterial diseases MORPHOCHEM GMBH (DE) 2022-03-01 — — US disclosed
CN-112089714-A Oxazolidinone-quinolone hybrid antibacterial agents for the parenteral treatment or prophylaxis of bacterial diseases 莫弗凯姆有限公司 2020-12-18 — — CN disclosed
US-20200392168-A1 OXAZOLIDINONE-QUINOLONE HYBRID ANTIBACTERIAL FOR THE PARENTERAL TREATMENT OF PROPHYLAXIS OF BACTERIAL DISEASES Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) 2020-12-17 — — US disclosed
EP-3003307-B1 COMBINATION THERAPY COMPRISING OXAZOLIDINONE-QUINOLONES FOR USE IN TREATING BACTERIAL INFECTIONS MORPHOCHEM GMBH (DE) 2020-11-11 — — EP disclosed
US-20070155714-A1 Use of oxazolidinone-quinoline hybrid antibiotics for the treatment of anthrax and other infections MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) 2007-07-05 — — US disclosed
US-20070155714-A1 Use of oxazolidinone-quinoline hybrid antibiotics for the treatment of anthrax and other infections MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) 2007-07-05 — — US disclosed
EP-1709044-A2 OXAZOLIDINONE-QUINOLONE HYBRID ANTIBIOTICS Morphochem Aktiengesellschaft Für Kombinatorische Chemie (DE) 2006-10-11 — — EP disclosed
WO-2005058888-A2 OXAZOLIDINONE-QUINOLONE HYBRID ANTIBIOTICS Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) 2005-06-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200392168-A1 OXAZOLIDINONE-QUINOLONE HYBRID ANTIBACTERIAL FOR THE PARENTERAL TREATMENT OF PROPHYLAXIS OF BACTERIAL DISEASES NQO2, QARS1, RECQL TOP2B 85/4885LMNA 3394/4885MAOA 2580/4885
US-20160130288-A1 OXAZOLIDINONE-QUINOLONE HYBRID ANTIBACTERIALS FOR THE PARENTERAL TREATMENT OR PROPHYLAXIS OF BACTERIAL DISEASES NQO2, OXA1L, QARS1 TOP2B 72/4885LMNA 3425/4885MAOA 2656/4885
US-20160113921-A1 COMBINATION THERAPY COMPRISING OXAZOLIDINONE-QUINOLONES FOR USE IN TREATING BACTERIAL INFECTIONS OXA1L, NQO2, NQO1 TOP2B 17/4885LMNA 4306/4885MAOA 2294/4885
US-20070155714-A1 Use of oxazolidinone-quinoline hybrid antibiotics for the treatment of anthrax and other infections OXA1L, ANTXR2, AAAS TOP2B 74/4885LMNA 2580/4885MAOA 1013/4885
US-10723746-B2 Oxazolidinone-quinolone hybrid antibacterials for the parenteral treatment or prophylaxis of bacterial diseases NQO2, OXA1L, QARS1 TOP2B 72/4885LMNA 3425/4885MAOA 2656/4885
US-11261205-B2 Oxazolidinone-quinolone hybrid antibacterial for the parenteral treatment of prophylaxis of bacterial diseases NQO2, QARS1, RECQL TOP2B 85/4885LMNA 3394/4885MAOA 2580/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.